Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival of glioma patients irrespectively of the MGMT methylation status.

Karlsson I, Veevnik D, Fedulov A, Yurkshtovich N, Yurkshtovich T, Pejler G, Lokot I.

Neoplasma. 2018 Dec 12. pii: 180613N393. doi: 10.4149/neo_2018_180613N393. [Epub ahead of print]

PMID:
30569719
2.

O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.

Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG, Karayan-Tapon L.

Int J Mol Sci. 2012;13(6):6983-94. doi: 10.3390/ijms13066983. Epub 2012 Jun 7.

3.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
4.

CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.

Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, García-Lopez JL, Piquer J, Safont MJ, Balaña C, Sanchez-Cespedes M, García-Villanueva M, Arribas L, Esteller M.

Clin Cancer Res. 2004 Aug 1;10(15):4933-8.

5.

Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.

Pyko IV, Nakada M, Sabit H, Teng L, Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS, Hamada J.

Carcinogenesis. 2013 Oct;34(10):2206-17. doi: 10.1093/carcin/bgt182. Epub 2013 May 28.

PMID:
23715499
6.

MGMT promoter methylation in plasma of glioma patients receiving temozolomide.

Fiano V, Trevisan M, Trevisan E, Senetta R, Castiglione A, Sacerdote C, Gillio-Tos A, De Marco L, Grasso C, Magistrello M, Tondat F, Rudà R, Cassoni P, Soffietti R, Merletti F.

J Neurooncol. 2014 Apr;117(2):347-57. doi: 10.1007/s11060-014-1395-4. Epub 2014 Feb 12.

7.

Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.

Cheng W, Li M, Jiang Y, Zhang C, Cai J, Wang K, Wu A.

J Neurosurg. 2016 Jul;125(1):7-16. doi: 10.3171/2015.5.JNS142437. Epub 2015 Nov 6.

PMID:
26544773
8.

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.

Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A.

JAMA Oncol. 2018 Oct 1;4(10):1405-1409. doi: 10.1001/jamaoncol.2018.1977.

PMID:
29955793
9.

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R.

Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21.

PMID:
18082451
10.

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.

Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW.

PLoS One. 2011 Feb 18;6(2):e17156. doi: 10.1371/journal.pone.0017156.

11.

O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.

Jha P, Suri V, Jain A, Sharma MC, Pathak P, Jha P, Srivastava A, Suri A, Gupta D, Chosdol K, Chattopadhyay P, Sarkar C.

Neurosurgery. 2010 Dec;67(6):1681-91. doi: 10.1227/NEU.0b013e3181f743f5. Review.

PMID:
21107199
12.

The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.

Park CK, Lee SH, Kim TM, Choi SH, Park SH, Heo DS, Kim IH, Jung HW.

J Neurooncol. 2013 Apr;112(2):277-83. doi: 10.1007/s11060-013-1060-3. Epub 2013 Feb 2.

PMID:
23377829
13.

Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.

Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J.

Cancer Res. 2007 Dec 15;67(24):11499-504.

14.

[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].

Zheng CQ, Ji SP, Gong F, Li AM, Tai JL, Zhang YP.

Ai Zheng. 2009 Jun;28(6):575-80. Chinese.

PMID:
19635193
15.

A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.

Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA.

Mol Cancer Ther. 2013 May;12(5):809-18. doi: 10.1158/1535-7163.MCT-12-0710. Epub 2013 Feb 26.

16.

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.

Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M.

Cancer. 2009 Aug 1;115(15):3512-8. doi: 10.1002/cncr.24406.

17.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
18.

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.

Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schläppi M, Moch H, von Moos R.

Oncol Rep. 2012 Aug;28(2):654-8. doi: 10.3892/or.2012.1826. Epub 2012 May 18.

PMID:
22614944
19.

O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.

Adachi J, Mishima K, Wakiya K, Suzuki T, Fukuoka K, Yanagisawa T, Matsutani M, Sasaki A, Nishikawa R.

J Neurooncol. 2012 Mar;107(1):147-53. doi: 10.1007/s11060-011-0721-3. Epub 2011 Oct 4.

PMID:
21968944
20.

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M.

J Neurochem. 2006 Feb;96(3):766-76. Epub 2006 Jan 9.

Supplemental Content

Support Center